MANE posts -$23.5M net loss in H1 2026 as Phase 3 spending rises; cash projects runway to 2030

Filed August 11, 2026 · Period ending June 30, 2026 · ~1 min read

Key Changes

• high

  Net loss widened 81% to $50.7M for the six months ended June 30, 2026 (vs $28.0M in H1 2025), driven by increased R&D spending on lead candidate VDPHL01 in Phase 3 trials for pattern hair loss.

  Notes: Operating losses and cash burn view on EDGAR →
• high

  Cash position of $819.9M as of June 30, 2026 projects runway into 2030 based on current operating plans.

  Notes: Liquidity and going concern assessment view on EDGAR →
• high

  VDPHL01 regulatory pathway remains undecided: company may pursue sequential approval (males first, then supplemental NDA for females) or simultaneous approval for both populations. FDA may require additional trials beyond current Phase 3 program.

  Risk Factors: VDPHL01 development and regulatory pathway verify on EDGAR →